PAH - phenylalanine hydroxylase Gene
Species: Sus scrofa
Gene Type: protein coding
Gene ID: 100521900
PAH Products (2)
| mRNA | Protein | Name |
|---|---|---|
| XM_021092656.1 | XP_020948315.1 | LOW QUALITY PROTEIN: phenylalanine-4-hydroxylase |
| XM_021092656.1 | XP_020948315.1 | LOW QUALITY PROTEIN: phenylalanine-4-hydroxylase |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
LOW QUALITY PROTEIN: phenylalanine-4-hydroxylase |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(9)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-A0124A | Sapropterin dihydrochloride | 99.82% | Yes | |
| HY-14184 | Macitentan | 99.87% | Yes | |
| HY-P0012 | Aviptadil | Inhibitor | 99.95% | Unkown |
| HY-A0126A | Epoprostenol sodium | Inducer | 98.03% | Unkown |
| HY-P0012A | Aviptadil acetate | Inhibitor | 99.87% | Unkown |
| HY-109013 | Sofpironium bromide | Inhibitor | 98.26% | Unkown |
| HY-A0124AR | Sapropterin dihydrochloride (Standard) | 99.96% | Unkown | |
| HY-14184A | Macitentan n-butyl analogue | 99.35% | Unkown | |
| HY-A0124 | Sapropterin | / | Unkown |
Clinical Phase
Bioactive Molecules
(9)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-A0126AR | Epoprostenol sodium (Standard) | / | Phase 4 | |
| HY-109112 | Brilaroxazine | 98.82% | Phase 3 | |
| HY-109190 | Seralutinib | Inhibitor | 99.94% | Phase 2 |
| HY-15472 | PRX-08066 | 97.46% | Phase 2 | |
| HY-101124 | Rodatristat ethyl | Inhibitor | 99.82% | Phase 2 |
| HY-15472A | PRX-08066 maleate | / | Phase 2 | |
| HY-B1727 | Phenanthrene | 99.82% | Phase 1 | |
| HY-129851 | NTP42 | Antagonist | 98.58% | Phase 1 |
| HY-170435 | PDE5-IN-13 | Inhibitor | / | Phase 1 |
Bioactive MoleculesInhibitory Antibodies
(2)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P990733 | Cibotercept | Inhibitor | 99.85% | Phase 2 |
| HY-P992008 | PF-07868489 | / | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(62)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-W011845 | DMBA | Inducer | 99.94% | Unkown |
| HY-15425 | PF-543 | 99.85% | Unkown | |
| HY-15425A | PF-543 Citrate | 99.47% | Unkown | |
| HY-103609 | Pyrene | 99.83% | Unkown | |
| HY-W014075 | 1-Hydroxypyrene | 99.38% | Unkown | |
| HY-161119 | Drpitor1a | Inhibitor | 96.95% | Unkown |
| HY-W026772 | Fluorene | 99.35% | Unkown | |
| HY-121107 | Chrysene | 99.81% | Unkown | |
| HY-Y1771 | 2-Carboxybenzaldehyde | 99.95% | Unkown | |
| HY-111450 | CB7993113 | Antagonist | 98.0% | Unkown |
| HY-W016103 | 1-Hydroxy-2-naphthoic acid | 99.70% | Unkown | |
| HY-W013570 | Acenaphthylene | 99.62% | Unkown | |
| HY-108464A | Phenamil methanesulfonate | Inhibitor | 98.1% | Unkown |
| HY-B1727S | Phenanthrene-d10 | 99.46% | Unkown | |
| HY-134620 | Cyanine 5 NHS ester tetrafluoroborate | 98.0% | Unkown | |
| HY-14184S | Macitentan-d4 | 99.85% | Unkown | |
| HY-N11222 | Nonanoylcarnitine | 99.87% | Unkown | |
| HY-W012278 | Benz[a]anthracene | Ligand | 99.90% | Unkown |
| HY-128593 | TPN171 | Inhibitor | 98.10% | Unkown |
| HY-121107S | Chrysene-d12 | 99.71% | Unkown | |
| HY-W014075S | 1-Hydroxypyrene-d9 | 99.95% | Unkown | |
| HY-177948 | GRK2 degrader-1 | Degrader | 98.83% | Unkown |
| HY-23498 | Benzo[k]fluoranthene | / | Unkown | |
| HY-RS09979 | PAH Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W026772S | Fluorene-d10 | 99.0% | Unkown | |
| HY-W026772S1 | Fluorene-d8 | / | Unkown | |
| HY-131973 | PDE10A-IN-2 hydrochloride | Inhibitor | 98.43% | Unkown |
| HY-174416 | Smurf1-IN-5 | Inhibitor | / | Unkown |
| HY-P3242 | Mad1 (6-21) | 98.02% | Unkown | |
| HY-Q43097 | Hsp110-STAT3 PPI-IN-1 | Inhibitor | 90% | Unkown |
| HY-120152A | SLP7111228 hydrochloride | Inhibitor | 98.01% | Unkown |
| HY-144856S1 | Sapropterin-d3 | / | Unkown | |
| HY-33451 | 4-Dibenzofurancarboxylic acid | 99.92% | Unkown | |
| HY-W013570S | Acenaphthylene-d8 | 99.48% | Unkown | |
| HY-W017708 | Triphenylene | 99.30% | Unkown | |
| HY-W777456 | Phenanthrene-13C6 | 99.9% | Unkown | |
| HY-15425B | PF-543 hydrochloride | / | Unkown | |
| HY-109013S | Sofpironium-13C,d3 bromide | Inhibitor | / | Unkown |
| HY-115477 | Brilaroxazine hydrochloride | / | Unkown | |
| HY-121025 | BUR1 | Inhibitor | 99.65% | Unkown |
| HY-149492 | Phosphatase-IN-1 | Inhibitor | 99.88% | Unkown |
| HY-155737 | ET receptor antagonist 1 | Inhibitor | / | Unkown |
| HY-155738 | ET receptor antagonist 2 | Inhibitor | / | Unkown |
| HY-155739 | ET receptor antagonist 3 | Inhibitor | / | Unkown |
| HY-167849 | Sofpironium tosylate | Inhibitor | / | Unkown |
| HY-167906S | Hexadecyl 2-((4-Nitrophenyl)thio)acetate-13C2 | / | Unkown | |
| HY-168178 | Hsp110-STAT3 PPI-IN-2 | Inhibitor | / | Unkown |
| HY-170387 | MRS8209 | Antagonist | / | Unkown |
| HY-170419A | APJ receptor agonist 10 free base | Agonist | 99.27% | Unkown |
| HY-D1549 | o-Pah | / | Unkown | |
| HY-N10021 | Benzo[e]pyrene | 98.0% | Unkown | |
| HY-P3242A | Mad1 (6-21) TFA | / | Unkown | |
| HY-W777458 | Fluorene-13C6 | / | Unkown | |
| HY-W778162 | Phenanthrene-13C2 | / | Unkown | |
| HY-108936 | QCC374 | Agonist | / | Unkown |
| HY-167906 | Lunamarine | Inhibitor | / | Unkown |
| HY-172508 | Perylene dU phosphoramidite | / | Unkown | |
| HY-19197 | 2-NAP | / | Unkown | |
| HY-RS17018 | Pah Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS23461 | Pah Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W016103R | 1-Hydroxy-2-naphthoic acid (Standard) | / | Unkown | |
| HY-W585976 | Benzo[a]pyrene diol epoxide | / | Unkown |